Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4003-4015

  Morningstar, Marshall L ^a   Roth, Thomas ^a   Farnsworth, David W ^a   Smith, Marilyn Kroeger ^a,b   Watson, Karen ^c   Buckheit Jr , Robert W ^c   Das, Kalyan ^d   Zhang, Wanyi ^d   Arnold, Eddy ^d   Julias, John G ^a   Hughes, Stephen H ^a   Michejda, Christopher J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCDANIEL COLLEGE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4 BROMOBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4 CHLOROBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4 METHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4 NITROBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4,5 DIMETHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4,6 DIMETHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 5 BROMOBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 5 CHLOROBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 5 METHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 5 NITROBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 6 CHLOROBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 6 METHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 7 METHYLBENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT;

BENZIMIDAZOLES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548128318     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060103d     Document Type: Article

References (24)

1. De Clercq, E. Highlights in the development of new antiviral agents Mini-Rev. Med. Chem. 2002, 2, 163-175.
2. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih Ch.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Franes, R.; Eckner, R.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
3. Pauwels, R.; Andries, K.; Debyser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Hekants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993 90, 1711-1715.
4. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenbogs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
5. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I.-W.; Schleif, W. A.; Sardane, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agnents Chemother 1995 39, 2602-2605.
6. Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; Tan, C.-K.; Voorman, R. L.; Reusser, F.; Althaus, I. W.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G.; Aristoff, P. A. Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 1994, 37, 999-1014.
7. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M.-P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(l£)- 2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 2005, 48, 1901-1909.
8. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
9. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
10. Roth, T.; Morningstar, M. L.; Boyer, P. L.; Hughes, S. H.; Buckheit, R. W.; Michejda, C. J. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J. Med. Chem. 1997, 40, 4199-4207.
11. Chimirri, A.; Grasso, S.; Monforte, A.-M.; Monforte, P.; Zappala, M. Anti-HIV agents. I. Synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Farmaco 1991, 46, 817-823.
12. Buckheit, R. W.; Hollingshead, M. G.; Germany-Decker, J.; White, E. L.; McMahon, J. B.; Allen, L. B.; Ross, L. J.; Decker, W. D.; Westbrook, L.; Shannon, W. M.; Weislow, O.; Bader, J. P.; Boyd, M. R. Thiazolobenzimidazole: biological and biochemical antiretroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 1993, 21, 247-265.
13. El Dareer, S. M.; Tillery, K. F.; Rose, L. M.; Posey, C. F.; Struck, R. F.; Stiller, S. W.; Hill, D. L. Metabolism and disposition of a thiazolobenzimidazole active against human immunodeficiency virus-1. Drug Metab. Dispos. 1993, 21, 231-235.
14. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231.
15. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.; Anold, E. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
16. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 557-586.
17. Yang, S.; Fliakas-Boltz, V.; Bader, J. P.; Buckheit, R. W. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia 1995, Suppl. 1, S75-S85.
18. Wood, J. L.; Khartri, N. A.; Weinreb, S. M. A direct conversion of esters to nitriles. Tetrahedron Lett. 1979, 51, 4907-4910.
19. Kroeger Smith, M. B.; Hose, B. M.; Hawkins, A.; Lipchock, J.; Farnsworth, D. W.; Rizzo, R. C.; Tirado-Rives, J.; Arnold, E.; Zhang, W.; Hughes, S. H.; Jorgensen, W. L.; Michejda, C. J.; Smith, R. H., Jr. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: Correlation of binding energy with biological activity for novel 2-aryl substituted benzimidazole analogues. J. Med. Chem. 2003, 46, 1940-1947.
20. Jorgensen, W. L. MCPRO, version 2.0; Yale University: New Haven, CT.
21. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D., Jr.; Moereels, H.; Koymans, L.; Andrias, K.; Pauwels, R.; Janssen, P. A.; Boyer, P. L.; Clark, P.; Smith, R. H., Jr.; Kroeger Smith, M. B.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal structure of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1996, 264, 1085-1100.
22. Otwinowski, Z.; Minor, W. DENZO and SCALEPACK. In The International Union of Crystallography: Crystallography of Biological Macromolecules; Rossmann, M. G., Arnold, E., Eds.; Kluwer Academic: Boston, MA, 2001; Vol. F, pp 226-235.
23. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47, 110-119.
24. Brunger, A. T.; Adams, P. D.; Rice, L. M. Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr. Opin. Struct. Biol. 1998, 8, 606-611.